HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Lepu Medical Technology A (300003 CH) - Does Not Have High Moat

Haier Biomedical (688139.CH) - Just Been Included in the FTSE GEIS, Time to Follow

Beijing Wantai Biological (603392.CH) - After A 3839% Rally, Let's Look at Some Concerns

JD Health (6618.HK) - Opportunities Coexist with Challenges

Pre-IPO JD Health (JDH.HK) - A Better Candidate of Online Healthcare Business In China?

Industry Report - Insights on China Digital Healthcare Industry

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Ping An Healthcare and Technology / Equity Bottom-Up

Ping An Healthcare and Technology (1833 HK)

<p><a href="https://www.smartkarma.com/entities/ping-an-healthcare-and-technology-company-limited" target="_blank" data-smartkarma-citation="entities:27008:1" rel="noopener">Ping An Healthcare and Technology Company Limited (1833 HK)</a> recently released the performance announcement for 2020. The Company’s revenue in 2020 was RMB6.87 billion, up 35.5% YoY. Net loss was RMB950 million, up 27% YoY, and the adjusted net loss fell 25.8% YoY to RMB516 million. Although the above financial data has some positive side, and recently the Company’s share price hit a historical new high (HK$148.5), considering the problems on its business, user base, management team, fierce competition and future challenges, perhaps it is the time to think of some concerns. </p>

Ping An Healthcare and Technology Company Limited (1833 HK) recently released the performance announcement for 2020. The Company’s revenue in 2020 was RMB6.87 billion, up 35.5% YoY. Net loss was RMB950 million, up 27% YoY, and the adjusted net loss fell 25.8% YoY to RMB516 million. Although the above financial data has some positive side, and recently the Company’s share price hit a historical new high (HK$148.5), considering the problems on its business, user base, management team, fierce competition and future challenges, perhaps it is the time to think of some concerns. 

Yixintang Pharmaceutical Group (002727 CH)

DaShenLin Pharmaceutical Group (603233 CH)

Ping An Good Doctor (1833.HK) - It Is the Time to Look at Some Concerns